- Home
- DRMA vs SLRX Comparison
DRMA vs SLRX Comparison
Compare DRMA & SLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRMA
- SLRX
- Stock Information
- Founded
- DRMA 2014
- SLRX N/A
- Country
- DRMA United States
- SLRX United States
- Employees
- DRMA N/A
- SLRX N/A
- Industry
- DRMA Biotechnology: Pharmaceutical Preparations
- SLRX Biotechnology: Pharmaceutical Preparations
- Sector
- DRMA Health Care
- SLRX Health Care
- Exchange
- DRMA Nasdaq
- SLRX Nasdaq
- Market Cap
- DRMA 2.2M
- SLRX 2.1M
- IPO Year
- DRMA 2021
- SLRX N/A
- Fundamental
- Price
- DRMA $1.33
- SLRX $2.69
- Analyst Decision
- DRMA Strong Buy
- SLRX
- Analyst Count
- DRMA 1
- SLRX 0
- Target Price
- DRMA $6.00
- SLRX N/A
- AVG Volume (30 Days)
- DRMA 230.6K
- SLRX 6.4M
- Earning Date
- DRMA 11-13-2024
- SLRX 11-14-2024
- Dividend Yield
- DRMA N/A
- SLRX N/A
- EPS Growth
- DRMA N/A
- SLRX N/A
- EPS
- DRMA N/A
- SLRX N/A
- Revenue
- DRMA N/A
- SLRX N/A
- Revenue This Year
- DRMA N/A
- SLRX N/A
- Revenue Next Year
- DRMA N/A
- SLRX N/A
- P/E Ratio
- DRMA N/A
- SLRX N/A
- Revenue Growth
- DRMA N/A
- SLRX N/A
- 52 Week Low
- DRMA $1.00
- SLRX $1.22
- 52 Week High
- DRMA $8.66
- SLRX $7.20
- Technical
- Relative Strength Index (RSI)
- DRMA 51.81
- SLRX 61.15
- Support Level
- DRMA $1.30
- SLRX $2.26
- Resistance Level
- DRMA $1.48
- SLRX $3.53
- Average True Range (ATR)
- DRMA 0.12
- SLRX 0.58
- MACD
- DRMA 0.00
- SLRX 0.11
- Stochastic Oscillator
- DRMA 49.66
- SLRX 20.60
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a clinical-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to develop and formulate singular and combination products that are able to target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases.
About SLRX Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.